Clinical Trial Search

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 — 9.3; 37.2; 58.1…

Primary: Blood Leukocyte Subpopulations: the Absolute Numbers of Leukocytes of Specific Phenotypes — 16.0; 11.2; 11.9; 4.9 10^9 cells/l — p=<0.05

Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab — 12.9; 13.5 microgram per milliliter (ug/mL)

Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants

Primary: Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection — 147; 395; 291 Participants

Primary: Proportion of Subjects Who Achieve ≥75% Overall Improvement in Eczema Area and Severity Index (EASI) Score From Baseline to Week 16. — 9.8; 18.1; 12.5; 15.1 percentage…

Primary: Client Satisfaction Questionnaire — 27; 22 Participants

Primary: Shared Decision-making — 12.54; 12.15 Units on a scale — p=0.8388

Primary: Enrollment Rate — 8.87 percentage of individuals approached

Primary: Efficacy in Hip Fracture Patients Confirmed by DXA Scan. — 0; 4.75; 7.15; 9.08 PBO adjusted percent change — p=0.0032

Primary: Change in Stigma Score From Baseline to End of Intervention in Protocol Group — 2.2358; 2.1760 score — p=0.05

Primary: Polymorphism of FCGR2 Gene — 29; 53; 36 Participants

Primary: Number of Participants Experiencing Clinical and/or Laboratory Dose-limiting Toxicities — 0 Participants

Primary: SP2Clin Metric — 22.6; 20.0 telehealth consults — p=0.5747

Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants